A Randomized Controlled Clinical Trial Testing Effects of Lademirsen on Kidney Function Decline in Adults with Alport Syndrome.

Daniel P Gale Oliver GrossFang WangRafael José Esteban de la RosaMatthew HallJohn Andrew SayerGerald AppelAli HaririShiguang LiuManish MaskiYuqian ShenQi ZhangSajida IqbalMadhurima Uppara KowthalamJulie LinJie Dingnull null

Published in: Clinical journal of the American Society of Nephrology : CJASN (2024)

While anti-microRNA-21 therapy with lademirsen was generally well-tolerated with an acceptable safety profile, no meaningful improvement in rate of kidney function decline in adults with Alport syndrome at risk of rapidly progressive disease was observed.

Keyphrases

case report
multiple sclerosis
bone marrow